Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387488-A1 | ACTIVE AGENT-ELUTING HEMOSTATIC AGENTS AND METHODS OF USE THEREOF | FLORIDA SOUTHERN COLLEGE (US) | 2025-12-25 | — | — | US | claimed |
| US-12397083-B1 | Active agent-eluting hemostatic agents for prevention of surgical site infection | FLORIDA SOUTHERN COLLEGE (US) | 2025-08-26 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024153111-A1 | LIPID CONJUGATES, LIPID NANOPARTICLES AND METHODS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-07-25 | — | — | WO | claimed |
| CN-117772170-A | Sludge biochar catalyst and preparation method and application thereof | 武汉纺织大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117379598-B | Polymer hydrogel and preparation method and application thereof | 天津医科大学口腔医院 | 2024-03-22 | — | — | CN | claimed |
| EP-4305051-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Shattuck Labs, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117379598-A | Polymer hydrogel and preparation method and application thereof | 天津医科大学口腔医院 | 2024-01-12 | — | — | CN | claimed |
| EP-4149482-A1 | 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION | Glycosyn LLC (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115453002-A | Method for simultaneously screening 16 antirheumatic chemical components illegally added in Chinese patent medicine | 芜湖市食品药品检验中心(市药品不良反应监测中心) | 2022-12-09 | — | — | CN | claimed |
| CN-111044516-B | Remote sensing estimation method for chlorophyll content of rice | 沈阳农业大学 | 2022-10-25 | — | — | CN | claimed |
| US-20220306715-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS, INC. | 2022-09-29 | — | — | US | claimed |
| WO-2022192236-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| EP-4021944-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Shattuck Labs, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-11324766-B2 | 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation | Glycosyn LLC (US) | 2022-05-10 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113996338-A | Composite photocatalyst and preparation method and application thereof | 广东工业大学 | 2022-02-01 | — | — | CN | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PTGS2 2731/4885PTGS1 3480/4885AKR1C3 4705/4885 |
| US-20250387488-A1 | ACTIVE AGENT-ELUTING HEMOSTATIC AGENTS AND METHODS OF USE THEREOF | CDC37, PYCARD, F8 | PTGS2 2709/4885PTGS1 2803/4885AKR1C3 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.